NCT07102862

Brief Summary

This study aims to investigate potential alterations in hemorheological parameters in adolescents with idiopathic scoliosis (AIS) compared to healthy controls. A total of 30 AIS patients and 30 age- and sex-matched healthy individuals will be evaluated through clinical, radiological, and laboratory assessments. Hematocrit, plasma and whole blood viscosity, erythrocyte deformability, and aggregation will be measured. The goal is to determine whether structural spinal deformities in AIS are associated with changes in microcirculatory blood flow properties.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 4, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 7, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 9, 2025

Completed
27 days until next milestone

First Posted

Study publicly available on registry

August 5, 2025

Completed
Last Updated

August 5, 2025

Status Verified

July 1, 2025

Enrollment Period

10 months

First QC Date

July 9, 2025

Last Update Submit

July 28, 2025

Conditions

Keywords

Idiopathic Adolescent Scoliosishemorheology

Outcome Measures

Primary Outcomes (6)

  • Plasma viscosity (PV)

    Measurement of plasma viscosity (mPa·s) using cone-plate viscometry at a shear rate of 450 s-¹.

    At baseline (single time point)

  • Whole blood viscosity (WBV)

    Measurement of whole blood viscosity (mPa·s) using cone-plate viscometer at multiple shear rates (37.5 to 450 s-¹).

    At baseline (single time point)

  • Erythrocyte deformability (EImax)

    Evaluation of erythrocyte elongation index (EImax) using laser-assisted ektacytometry (Lorrca MaxSis).

    At baseline (single time point)

  • Erythrocyte deformability (SS1/2)

    Evaluation of shear stress at half EImax (SS1/2) using laser-assisted ektacytometry (Lorrca MaxSis).

    At baseline (single time point)

  • Erythrocyte aggregation (AI and Tr)

    Measurement of aggregation index (AI) using Lorrca MaxSis at 37°C under standardized conditions.

    At baseline (single time point)

  • Erythrocyte aggregation (Tr)

    Measurement of relaxation time (Tr) using Lorrca MaxSis at 37°C under standardized conditions.

    At baseline (single time point)

Secondary Outcomes (42)

  • Correlation between Cobb angle and the Plasma viscosity (mPa·s)

    At baseline (single time point)

  • Correlation between cervical lordosis angle and the Plasma viscosity (mPa·s)

    At baseline (single time point)

  • Correlation between thoracic kyphosis angle and the Plasma viscosity (mPa·s)

    At baseline (single time point)

  • Correlation between lumbar lordosis angle and the Plasma viscosity (mPa·s)

    At baseline (single time point)

  • Correlation between angle of trunk rotation (ATR) and the Plasma viscosity (mPa·s)

    At baseline (single time point)

  • +37 more secondary outcomes

Study Arms (2)

Patients

10-18 years old AIS patients

Control Healthy Subjects

Sex and aged match healthy subjecyts

Eligibility Criteria

Age10 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

This case-control study occurred at the University of Health Sciences in Istanbul from January to May 2025. Participation was voluntary, and written informed consent was obtained from both the adolescents and their legal guardians prior to data collection. Adolescents with idiopathic scoliosis will initially be recruited. An equal number of age-matched and sex-matched healthy controls will also be included. All participants will undergo the same evaluation protocol, and inclusion/exclusion criteria will be applied consistently across both groups.

You may qualify if:

  • Presence of structural scoliosis with a Cobb angle greater than 10°
  • Age between 10 and 18 years

You may not qualify if:

  • Other types of scoliosis, such as syndromic conditions, congenital vertebral deformities, and neuromuscular scoliosis
  • Presence of any diseases or conditions that may affect hemorheology, such as cardiovascular, respiratory, and hematologic diseases
  • Obesity (Body mass index \[BMI\] \> 30)
  • Being treated surgically for scoliosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Health Sciences

Istanbul, Turkey (Türkiye)

Location

Related Links

Biospecimen

Retention: SAMPLES WITHOUT DNA

blood

Study Officials

  • Papatya Keles, professor

    Saglik Bilimleri Universitesi

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

July 9, 2025

First Posted

August 5, 2025

Study Start

April 4, 2024

Primary Completion

January 20, 2025

Study Completion

June 7, 2025

Last Updated

August 5, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Individual participant data (IPD) will not be shared due to privacy concerns and institutional policies. The data contains sensitive health information that cannot be sufficiently de-identified for public distribution.

Locations